LYELLyell Immunopharma, Inc.Signing up patients
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Large B-cell Lymphoma · Lymphoma, B-Cell · Relapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma Refractory/ Relapsed · Diffuse Large B Cell Lymphoma (DLBCL) · Diffuse Large B Cell Lymphoma Refractory · Diffuse Large B Cell Lymphoma Relapsed
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.1
4 insiders sold shares within a month
Since Aug 21, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- Jan 12, 2026
- Main results expected
- Dec 2029
- Fully finished
- Jan 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event free survival
Measured over: 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.1, since 2026-08-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07188558 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC